DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

"DHE plays a unique clinical role in the acute treatment of migraine, providing patients long-lasting effects and the unique ...

The Trump administration has proposed terminating a $56 million annual grant program that distributes naloxone, also known by ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

A budget proposal from President Donald Trump’s administration would cut a federal grant that provides $56 million annually ...

A drug derived from ketamine will be added to the PBS, helping tens of thousands of Australians struggling with depression to ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...

Naloxone, which can reverse overdoses of opioids, has been available in the U.S. without a prescription since March of 2023, ...

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who ...

Kindeva Drug Delivery, located off of Newtown Pike and Citation Boulevard, specializes in manufacturing life-saving ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.